We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.265 | 0.64% | 41.875 | 42.03 | 41.65 | 41.75 | 1,003,126 | 16:19:38 |
From Apr 2019 to Apr 2024
By Alex MacDonald
LONDON--U.K.-listed drug manufacturer GlaxoSmithKline PLC (GSK.LN) said Wednesday that it has begun the third phase trial of a pulmonary inhalement drug aimed at simplifying the treatment of chronic obstructive pulmonary disease.
The drug treatment, called FF/UMEC/VI, is aimed at patients who receive three medicines in different inhalers to treat the pulmonary disease and for whom a once-daily treatment in a single 'closed' device would be valuable, the company said.
Chronic obstructive pulmonary disease is a disease of the lungs that includes chronic bronchitis, emphysema or both. The disease interferes with normal breathing.
"The IMPACT study will be important in advancing our understanding of how the combination of FF/UMEC/VI could be used in this setting when compared to dual combination therapy options," said Dave Allen, Head of GSK's R&D Respiratory Therapy Area Unit.
The IMPACT study will enrol approximately 10,000 patients.
-Write to Alex MacDonald at alex.macdonald@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
